Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | DTYMK | P23919 | 4/20 | 0.61 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.58 |
| ▸ | TK1 | P04183 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.57 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.57 |
| ▸ | TYMS | P04818 | 1/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.57 |
| ▸ | POLD1 | P28340 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153654 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL1521215 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL1521248 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL14262431 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL1521074 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL1520996 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL1521353 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL1521023 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL15756213 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 | |
| SCHEMBL31153245 | 1.00 | POLB (0.63) | POLBDTYMKP2RY6TK1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742094-B2 | Method for the solid phase-based production of phosphate-bridged nucleoside conjugates | UNIVERSITAET HAMBURG (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | UNIVERSITAET HAMBURG (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116067-A1 | METHOD FOR THE SOLID PHASE-BASED PRODUCTION OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES | PNP, TYMP, DPYD | POLB 189/4885DTYMK 14/4885P2RY6 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.